Efficacy and safety of vitamin C in the management of acute respiratory infection and disease: A rapid review

Janet Schlossa,*, Romy Lauchea, Joanna Harnetteb, Nicole Hannanc, Danielle Brownad,cd, Tom Greenfielde, Amie Steele

a National Centre for Naturopathic Medicine, Southern Cross University, Lismore, New South Wales, Australia
b School of Pharmacy, University of Sydney, Sydney, New South Wales, Australia
c School of Pharmacy, Griffith University, Gold Coast, Queensland, Australia
d Endeavour College of Natural Health, Brisbane, Queensland, Australia
e Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, New South Wales, Australia
f Greenfields Clinic, Canterbury, United Kingdom

1. Background

Vitamin C is an essential micronutrient involved in various cellular functions of both the innate and adaptive immune systems. Vitamin C accumulates in phagocytic cells, such as neutrophils, through which it can enhance chemotaxis, phagocytosis, and generation of reactive oxygen species. Vitamin C is also involved with apoptosis and clearance of used neutrophils from sites of infection by macrophages thereby reducing potential tissue damage. Vitamin C also supports differentiation and proliferation of B- and T- cells [1].

Vitamin C was proposed as a potential useful agent for coronaviruses in 2003 when the SARS coronavirus was active [2] based on available evidence that vitamin C affects severe viral respiratory tract infections. Hemila [2], who has continued researching vitamin C for ARI, presented this hypothesis based on the evidence of vitamin C's non-specific effects on severe viral respiratory tract infections. This raises queries regarding vitamin C's potential application in the management of COVID-19.

2. Search strategy

2.1. Research question

What is the effect of Vitamin C on acute respiratory tract infections in adults when administered at the onset of symptoms?
2.2. Inclusion/exclusion criteria

2.2.1. Inclusion criteria
- Systematic review of clinical trials
- No age restrictions
- Administration at onset of symptoms of acute respiratory tract infection
- Oral or intravenous administration of Vitamin C

2.2.2. Exclusion criteria
- Prophylactic administration

2.3. Databases

Medline (Ovid), Embase (Ovid), AMED (Ovid), CINAHL (EBSCO)

Search terms (examples)

2.3.1. Ovid medline
(Systematic Review/ or Meta-analysis/ or Systematic Review as Topic/ or Meta-Analysis as Topic/ or Review Literature as Topic/ or (Systematic review or meta analy$ or metaanaly$).ti,ab,kw.) not (comment/ or letter/ or editorial/) AND Influenza, Human/ or Influenza A Virus, H1N1 Subtype/ or Influenza A virus/ or Influenza A Virus, H3N2 Subtype/ or Middle East Respiratory Syndrome Coronavirus/ or respiratory tract infections/ or bronchitis/ or common cold/ or exp sinusitis/ or (Influenza or H1N1 or MERS–COV or flu or Bronchit* or sinusit* or rhinosinusit* or rhinit* or common cold or (respiratory adj2 ( Infect* or illness or symptom* or acute or virus* or disease))).ti,ab,kw. AND exp Ascorbic Acid/ or (ascorbic acid or Vitamin c).ti,ab,kw (Table 1).

2.3.2. CINAHL EBSCO
PT systematic review OR PT meta-analysis or (MH “Systematic Review”) OR “systematic review” OR (MH “Cochrane Library”) OR (MH “Meta Analysis”) OR TX meta analy$ OR TX metaanaly$ OR TX systematic* review AND (MH “Influenza*”) OR (MH “Influenza A Virus*”) OR (MH “Influenza, Pandemic (H1N1) 2009”) OR (MH “Influenza A H5N1”) OR (MH “Influenza virus C”) OR (MH “Influenza B Virus”) OR (MH “Influenza A Virus, H1N1 Subtype”) OR (MH “Influenza, Swine”) OR (MH “Influenza, Human+*”) OR (MH “Influenza, Seasonal”) OR (MH “Influenza A Virus, H5N1 Subtype”) OR (MH “Influenza A Virus, H3N2 Subtype”) OR (MH “Cold+*”) OR (MH “Rhinitis”) OR (MH “Rhinosinusitis”) OR (MH “Severe Acute Respiratory Syndrome”) OR (MH “Sinusitis”) OR (MH “Bronchitis”) OR (MH “Bronchitis, Acute”) OR (MH “Common Cold”) OR (MH “Respiratory Tract Infections”) OR TX influenza OR TX H5N1 OR TX Common Cold OR TX Rhinitis OR TX Rhinosinusitis OR TX Bronchitis OR TX H3N2 OR (TX Respiratory N2 (Infect* OR illness* OR symptom* OR acute OR virus* OR disease*)) AND (MH “Ascorbic Acid”) OR TX “vitamin c” OR TX “Ascorb* acid”

2.4. Critical appraisal

The critical appraisal tool used to assess the studies in this rapid review was the BMJ Best practice, appraising systematic reviews (https://bestpractice.bmj.com/info/toolkit/learn-ebm/appraising-systematic-reviews/).

3. Rapid review results

A search conducted across 4 databases identified 141 review articles. Following the removal of 34 duplicates, 107 review articles were screened by title and abstract for relevance to the study question. Of these, 36 full-text literature reviews were assessed for eligibility against the pre-defined inclusion criteria. A total of 31 articles were removed due to not meeting one or more of the criteria as follows: different patient population (4), study design (14), intervention type (3), not an adult population (3), study setting (1), not written in English (1), indication (2), reviews of reviews (3), the remaining 6 articles were included in this rapid review.

3.1. Critical appraisal

From the appraisal, three of the five systematic reviews met all the requirements [4,5,7]. One systematic review met the majority of the requirements with the reviewers unable to verify if combined primary studies and combined statistical results were correct [6]. The last review was considered to have a lower level of evidence for a systematic review but was still adequate [3]. Overall, the level of evidence for the reviews chosen were adequate.

3.2. Summary of findings

All five studies were systematic reviews of randomised controlled trials (RCTs) [1–4]. Two of the studies included a meta-analysis of the included study data [2,4]. The study populations and size, type of respiratory condition, form and dose, and administration route of vitamin C varied across the studies reviewed. The measurement outcomes reviewed by each study varied and were specific to the study focus.

Hemila’s 2004 systematic review included eight double-blind randomised-controlled trials, two controlled trials and two studies with poorly defined designs conducted between 1999 and 2002. A total of 1979 participants who were military personal and 587 athletics students in crowded lodgings and marathon runners were allocated to receive vitamin C with doses ranging from 0.05 to 2 g/d for 7 days to 6 months. The severity and duration of respiratory infections were measured in addition to the number of hospital admissions. Overall, positive findings were reported for the severity of respiratory tract infections. The authors suggested the results should be interpreted with caution due to the heterogeneity in study designs including formulation, dose, dietary intake of vitamin C, and the degree of participant’s physical exertion [1].

Hemila’s 2013 meta-analysis included 3 controlled clinical trials involving 79 (children and adults) evaluating the efficacy of ascorbic acid as single or multiple oral doses for different lengths of time (1 g/d for 14 weeks, 2 g/d one dose at two time points, 5 g/d for 2 weeks) in reducing the incidence and severity of common cold induced asthma. The primary endpoints across the studies were frequency of asthma attacks, sensitivity to asthma symptoms scores, peak expiratory flow, histamine sensitivity and severity of olds. Significant reductions in the incidence RR = 0.22 (0.06 to 0.81) and severity of asthma attacks RR = 0.22 (0.06 to 0.81) and a 52 % reduction in participants sensitive to histamine sensitivity as measured by PC20 levels [2].

Hemila and Chalkers 2013 systematic review included 29 trial comparisons involving a total of 11,306 participants to identify whether vitamin C reduces the incidence, the duration or severity of the common cold. The studies included were from inception to 2013. Collectively the studies involved 10,708 participants from the general community and 598 participants which exercised in extreme conditions. Of the 31 comparisons analysed on people taking vitamin C it was found to reduce the duration of the common cold and the severity of symptoms. No consistent effects were seen on studies evaluating the use of vitamin C during the common cold on duration or severity [3].

Hemila and Louhiala [5] systematic review included six controlled trials comprising a range of populations (elderly,
Table 1
Summary of systematic reviews of vitamin C in the management of acute respiratory infection and disease.

| Author                     | Year | Type of Review | Review duration | Types of Studies included | Databases Used                                                                 | Intervention | Participants included (condition of interest) | Studies included (number of types of studies) | Interventions and dose | Number of Studies (method and dose) | Administration of Vitamin C | N in intervention and placebo | Measure of Outcome |
|----------------------------|-----|----------------|-----------------|---------------------------|-------------------------------------------------------------------------------|--------------|-----------------------------------------------|-----------------------------------------------|------------------------|----------------------------------|-----------------------------|---------------------------|-------------------------|
| Hemila 2013                | Meta-analysis | 2013 | Oral or intravenous vitamin C (ascorbic acid or its salts) in a single or multiple doses | Medline (OVID), Scopus, Cochrane Central Register of Controlled Trials | 1980–1990 | Not specified | 2 x randomised, double-blind placebo-controlled trials (1 x cross-over) | N=79 | 1 g/day: 5 g/day; 2 g single dose | 2 placebo x 2; no control x 1 | Vit C (22 + 23 + 54); placebo (19 + 23 + 42) | Incidence of all asthma attacks; RR = 0.22; Incidence of severe and moderate asthma attacks; RR = 0.11 |
| Hemila 2004                | Systematic review | 1999–2002 | Military personnel: students in crowded lodgings, marathon runners (respiratory infections) | Medline, EMBASE, SCISearch, EMBASE, Web of Science | 1942–1996 | 8 x randomised, double-blind placebo-controlled trials; 2 x non-placebo-controlled trial; 2 x poorly described methodology | N=194 | 0.05–2 g/day for 7 days - 6 months | placebo x 2; no control x 2 | Uncontrolled | Severity of colds; duration of colds (days); Incidence and duration of specific symptoms; Vit C (vit c = 561; control = 831) | No statistical difference |
| Hemila and Chalker 2013    | Systematic review | 2010–2012 | Children and adults of either gender and any age (common cold) | CENTRAL, MEDLINE, Embase, CINAHL, LISAC, Web of Science | 1950–2001 | 17 x placebo-controlled trials in community; 3 placebo-controlled laboratory trials | N = 3249 | 1–8 g/day for 1–4 days | Placebo | Placebo x 2; no control x 1 | Vit C (vit c = 1968; control = 1282); placebo (372) | No statistical difference |
| Hemila and Louhiala 2017   | Systematic review | 1950–2011 | Vitamin C only (ascorbic acid or its salts) to one trial group, orally or IV as a single dose (allowed in treatment studies) or multiple doses, with no other nutrient substances | Cochrane Central Register of Controlled Trials, Web of Science | 1970–1994 | 1 x oral dietary fortification; 4 x not specified | N = 2532 | 0.05 to 0.3 g/day for 6 months; 0.2 g/day for up to 4 weeks; 0.3 g/day for unspecified duration; 2 mg per 2000 antibiotic units (0.05–16.9 g/day) or 1 mg per 2000 antibiotic units (0.025 to 0.08 g/day) for unspecified duration | 2 x no placebo; 1 x low-dose vitamin C used as placebo in primary comparison; 2 x placebo | Placebo | Community-acquired; Severity of pneumococcal episodes | No statistical difference | Reduced severity score (2.31) at four weeks (p = 0.03) for patients with higher respiratory scores on admission; no statistical difference (p > 0.05) | No evidence available |
| Author          | Year | Type of Review | Review duration | Types of Studies Included | Databases Used          | Intervention | Participants included (condition or interest) | Participants included (condition of interest) | Number of Studies included | The number of Types of Studies included | Administration of Vitamin C | Total number of participants in the Review | Div | Control or Placebo | N in intervention and placebo | Measure of Outcome | Outcome |
|-----------------|------|----------------|-----------------|---------------------------|-------------------------|---------------|-----------------------------------------------|-----------------------------------------------|----------------------------|--------------------------------------|-----------------------------|------------------------------------------|-----|------------------|--------------------------------------|--------------------------|---------|
| Ran et al 2018  | Systematic review and meta-analysis | Inception to March 2018 | randomised controlled trials | PubMed, Cochrane Library, Elsevier, CNKI, VIP databases, WANFANG | vitamin C, added as a regular supplement or administered as needed when cold symptoms developed | definitive diagnosis of common cold based on laboratory examination, clinical signs, or reported symptoms; no limitation in age, sex, occupation | 9 x randomised placebo-controlled trials | Oral | n = 5722 + 1 study n = not reported | from 0.67 g per 4 h (4 g over 24 h) to max 10 doses; 1300 mg on day 1 after 500 mg/day; max 8 g on day 1 | all studies used unspecified placebo | Vit C 2564; control 2076; unspecified; 1 study not reported | Mean duration; nasal congestion or runny nose; sore throat; aching limbs and muscles; mental depression; fever | significantly better at reducing fever by about 0.5 days (MD = -0.45, 95% CI [-0.78, -0.11], and P = 0.009) | No evidence available |
| Zhang and Jativa 2018 | Excluded as participant did not have ARI |
| Hemmer 2009 | Excluded as it is a review of reviews |
| Hemila 1994 | Excluded as superceded by Hemila 2013 |
| Hemila 1999 | Excluded as supplementation was initiated with healthy subjects |
| Nabas and Bulia 2011 | Excluded as the vitamin C part was a review of reviews |
| Rondanelli et al 2018 | Excluded as it is a narrative review |
boarding school male students, burns patients, and military personnel) and varied study designs (non-placebo and placebo-controlled studies). Five studies involved the oral administration or vitamin C (200 mg–3000 mg) in either the prevention (n = 3) or treatment (n = 2) of community-acquired pneumonia and 1 study administered intravenous vitamin C (66 mg/kg/h) during the 24 h after admission to a burns unit to prevent hospital-acquired pneumonia. The three trials examining continuous oral vitamin intake reported 37 cases of community-acquired pneumonia amongst 2335 people and found that vitamin C reduced the incidence of pneumonia by 80 %. The two treatment trials involving 197 community-acquired pneumonia patients and one prophylactic trial recorded 13 cases of hospital-acquired pneumonia across 37 patients. Rans 2018 meta-analysis including nine RCTs and 3796 participants with a definitive diagnosis of the common cold based on laboratory examination, clinical signs, or reported symptoms from a broad demographic and conducted between 1950 and 2001, evaluating the effectiveness of vitamin C doses ranging from 500 mg to 8 g per day in the treatment of the common cold symptoms. No statistically significant effects were observed for nasal congestion or runny nose, sore throat, aching limbs and muscles or mental depression. Statistically significant improvements were identified for the symptoms of fever ($p = 0.009$), chest pain ($p = 0.03$) and chills (0.01) and being confined in doors was reduced by half a day ($p = 0.004$) [4].

4. Clinical significance

The evidence from this rapid review has identified that oral vitamin C may assist with the symptoms of acute respiratory viral infections (ARI) and common cold-induced asthma but no studies have been identified justifying oral vitamin C for the prevention or treatment of conditions similar to COVID-19. When taken at onset of ARI, oral vitamin C may reduce the duration of AR symptoms including fever, chest pain, chills and bodily aches and pains. It may also reduce the incidence of hospital admission and duration of hospital stay.

Evidence related to IV vitamin C from this literature review for COVID-19 or similar conditions is very limited due to the reviews not specifying IV versus oral administration. However, from the studies included in these reviews, further investigation is warranted to examine the effect of IV vitamin C as an adjunct to current medical treatment in acute COVID-19 patients. In addition, oral administration at onset of symptoms to reduce duration and severity of COVID-19 infection also warrants further investigation. Current evidence suggests further studies are needed to better understand the value of both oral and IV vitamin C for ARI, including COVID-19.

Disclaimer

This article should not replace individual clinical judgement. The views expressed in this rapid review are the views of the authors and not necessarily from the host institutions. The views are not a substitute for professional medical advice. This is a rapid review of systematic reviews, and it should be noted that the original research papers included in each of the reviews included here, were not individually examined by the authors of this rapid review.

Funding

There was no funding for this project.

Acknowledgement

We would like to acknowledge the World Naturopathic Federation (WNF) for organising this rapid review.

References

[1] H. Hemilä, Vitamin C supplementation and respiratory infections: a systematic review, Mil. Med. 169 (11) (2004) 920–925,
[2] H. Hemilä, Vitamin C and common cold-induced asthma: a systematic review and statistical analysis, Allergy Asthma Clin. Immunol. 9 (1) (2013) 46.
[3] H. Hemilä, E. Chalker, Vitamin C for preventing and treating the common cold, Cochrane Database Syst. Rev. 1 (2013).
[4] L. Rans, W. Zhao, J. Wang, H. Wang, Y. Zhao, Y. Tseng, H. Bu, Extra dose of vitamin C based on a daily supplementation shortens the common cold: a meta-analysis of 9 randomized controlled trials, BioMed Research International 2018, (2018).
[5] H. Hemila, Louhala, Vitamin C for preventing and treating pneumonia review, Cochrane Database Syst Rev. Issue 8 (2013).
[6] A.C. Carr, S. Maggini, Vitamin C and immune function, Nutrients. 9 (11) (2017) 1211, doi:http://dx.doi.org/10.3390/nu9111211.
[7] H. Hemila, Vitamin C and SARS coronavirus, J Antimicrob Chemother 52 (6) (2003) 1049–1050, doi:http://dx.doi.org/10.1093/jac/dkh002.